Increased Risk Of Subclinical Acute Interstitial Nephritis Associated With The Use Of Proton Pump Inhibitors (Ppis) Leading To Acute Kidney Injury And/or Chronic Renal Failure

Increased Risk Of Subclinical Acute Interstitial Nephritis Associated With The Use Of Proton Pump Inhibitors (Ppis) Leading To Acute Kidney Injury And/or Chronic Renal Failure

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of an increased risk of subclinical acute nephritis associated with the use of PPIs leading to chronic renal inflammation and reduced renal function.

2021 Feb

Download latest version
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance